Billal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, Claire Mignard, Marie-Laure Golinski, Sébastien Calbo, Catherine Prost-Squarcioni, Bruno Labeille, Catherine Picard-Dahan, Guillaume Chaby, Marie-Aleth Richard, Emmanuelle Tancrede-Bohin, Sophie Duvert-Lehembre, Emmanuel Delaporte, Philippe Bernard, Frédéric Caux, Marina Alexandre, Philippe Musette, Saskia Ingen-Housz-Oro, Pierre Vabres, Gaëlle Quereux, Alain Dupuy, Sébastien Debarbieux, Martine Avenel-Audran, Michel D'Incan, Christophe Bédane, Nathalie Bénéton, Denis Jullien, Nicolas Dupin, Laurent Misery, Laurent Machet, Marie Beylot-Barry, Olivier Dereure, Bruno Sassolas, Jacques Benichou, Pascal Joly, Vivien Hébert
IMPORTANCE: The Ritux 3 trial demonstrated the short-term efficacy and safety of first-line treatment with rituximab compared with a standard corticosteroid regimen in pemphigus. No data on the long-term follow-up of patients who received rituximab as first line are available. OBJECTIVE: To assess the long-term efficacy and safety of the Ritux 3 treatment regimen. DESIGN, SETTING, AND PARTICIPANTS: This 7-year follow-up study of the Ritux 3 trial included patients with pemphigus from 25 dermatology departments in France from January 1, 2010, to December 31, 2015...
January 24, 2024: JAMA Dermatology